Physician profile
Peter Gottlieb
NPI 1174537492
$33,859.82
in general payments reported to CMS, 2019-2025
12 companies · $22K in 2025
The $22K reported for 2025 was more than what 93% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,720 · 2020: $450 · 2023: $20.00 · 2024: $6,053 · 2025: $22K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $25K · Food and Beverage: $1,228 · Travel and Lodging: $1,095 · Education: $20.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $25,346.91 |
| Food and Beverage | $1,228.14 |
| Travel and Lodging | $1,095.04 |
| Education | $20.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $18,479.21 | 2025 | |
| Sanofi-Aventis U.S. LLC | $5,973.86 | 2024-2025 | |
| Pfizer INC. | $3,980.00 | 2019 | |
| Eli Lilly and Company | $1,650.00 | 2025 | |
| Novo Nordisk As | $1,395.00 | 2025 | |
| Janssen Research & Development, LLC | $1,240.00 | 2019 | |
| Tandem Diabetes Care, INC. | $500.00 | 2019 | |
| Daiichi Sankyo INC. | $399.72 | 2020 | |
| Insulet Corporation | $172.02 | 2024 | Omnipod |
| Astrazeneca Pharmaceuticals LP | $50.01 | 2020 | |
| Mannkind Corporation | $20.00 | 2023 | Afrezza |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Gottlieb listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.